CVP system meets the need for an integrated solution to reproducibly purify viral RNA from respiratory samples and allow one-tube setup of sensitive RT-PCR
Qiagen says public health experts recommend its technologies for the reliable detection of human coronavirus in Sars, otherwise known as coronavirus pneumonia (CVP).
The new Qiagen CVP system meets the need for an integrated solution to reproducibly purify viral RNA from respiratory samples and allow one-tube setup of sensitive RT-PCR.
The Qiagen CVP system combines high-efficiency QIAamp RNA purification technology with reliable processing of low-volume respiratory samples in under 40 minutes - providing a solid foundation for reliable detection of coronavirus using CDC-recommended primers.
Qiagen RT-PCR technology streamlines validation and reaction setup through optimised buffers and a single-tube format to deliver increased sample throughput.
The unique blend of Omniscript and Sensiscript reverse transcriptases and HotStarTaq DNA polymerase provides the basis for robust and reproducible viral detection by RT-PCR.
